Literature DB >> 24710365

To foster screening, new colon cancer tests emphasize convenience.

Cassandra Willyard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24710365     DOI： 10.1038/nm0414-322

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.

Authors:  Uri Ladabaum; John Allen; Michael Wandell; Scott Ramsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-06-24       Impact factor: 4.254

2.  Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.

Authors:  Samir Gupta; Ethan A Halm; Don C Rockey; Marcia Hammons; Mark Koch; Elizabeth Carter; Luisa Valdez; Liyue Tong; Chul Ahn; Michael Kashner; Keith Argenbright; Jasmin Tiro; Zhuo Geng; Sandi Pruitt; Celette Sugg Skinner
Journal:  JAMA Intern Med       Date:  2013-10-14       Impact factor: 21.873

3.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

4.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.

Authors:  Timothy Robert Church; Michael Wandell; Catherine Lofton-Day; Steven J Mongin; Matthias Burger; Shannon R Payne; Esmeralda Castaños-Vélez; Brent A Blumenstein; Thomas Rösch; Neal Osborn; Dale Snover; Robert W Day; David F Ransohoff
Journal:  Gut       Date:  2013-02-13       Impact factor: 23.059
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.